Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2015

01-09-2015 | Commentary

Letter regarding Zhang et al. entitled “Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma”

Authors: Ke-wei Zhu, Wan-chun Wang, Ren Wu, Ding Chen

Published in: Tumor Biology | Issue 9/2015

Login to get access

Excerpt

To the Editor, …
Literature
1.
Zhang FY, Tang W, Zhao XW, et al. Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma. Tumor Biol. 2014;35:10419–27.CrossRef
2.
Gaetano B, Cristiana F, Stefano F, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol. 2003;25:845–53.CrossRef
3.
Meyers PA, Gorlick R, Hellr G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452–8.CrossRefPubMed
4.
Bacci G, Gherlinzoni F, Picci P, et al. Adriamycin-methotrexate high dose as versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. Eur J Clin Oncol. 1986;22:1337–45.CrossRef
5.
Souhami L, Craft AW, Van der Eijken JW, et al. Randomized trial of two regimens of chemotherapy in operative osteosarcoma: a study of the European Osteosarcoma intergroup. Lancet. 1997;350(9082):911–7.CrossRefPubMed
6.
Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol. 2009;27:2536–41.CrossRefPubMedPubMedCentral
Metadata
Title
Letter regarding Zhang et al. entitled “Systematic review of high-dose and standard-dose chemotherapies in the treatment of primary well-differentiated osteosarcoma”
Authors
Ke-wei Zhu
Wan-chun Wang
Ren Wu
Ding Chen
Publication date
01-09-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3910-4

Other articles of this Issue 9/2015

Tumor Biology 9/2015 Go to the issue

Retraction Note

Retraction Note to: Relationship between VEGF protein expression and lymph node metastasis in papillary thyroid carcinoma among Asians: a meta-analysis

Research Article

MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET

Research Article

The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer

Research Article

Role of Lgr5-positive cells in colorectal cancer

Research Article

A polysaccharide from the alkaline extract of Glycyrrhiza inflata induces apoptosis of human oral cancer SCC-25 cells via mitochondrial pathway

Retraction Note

Retraction Note to: Aberrant promoter methylation of the CHD1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits